These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 20701957)
1. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells. Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957 [TBL] [Abstract][Full Text] [Related]
2. [Influence of estrogen and progestin on nm23-H1 expression in epithelial ovarian cancer cell lines via activation of phosphorylation signaling]. Hua KQ; Yao LQ; Cao Q; Huang Y; Zhao YQ; Feng YJ Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):756-61. PubMed ID: 17327034 [TBL] [Abstract][Full Text] [Related]
3. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary. Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242 [TBL] [Abstract][Full Text] [Related]
5. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581 [TBL] [Abstract][Full Text] [Related]
6. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Esheba GE; Pate LL; Longacre TA Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882 [TBL] [Abstract][Full Text] [Related]
7. Glypican-3 expression in primary and recurrent ovarian carcinomas. Stadlmann S; Gueth U; Baumhoer D; Moch H; Terracciano L; Singer G Int J Gynecol Pathol; 2007 Jul; 26(3):341-4. PubMed ID: 17581422 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line. Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840 [TBL] [Abstract][Full Text] [Related]
9. Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling. Sung YK; Hwang SY; Farooq M; Kim JC; Kim MK Exp Mol Med; 2003 Aug; 35(4):257-62. PubMed ID: 14508064 [TBL] [Abstract][Full Text] [Related]
10. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells. Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456 [TBL] [Abstract][Full Text] [Related]
11. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Kandil DH; Cooper K Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373 [TBL] [Abstract][Full Text] [Related]
12. E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. De Santis G; Miotti S; Mazzi M; Canevari S; Tomassetti A Oncogene; 2009 Mar; 28(9):1206-17. PubMed ID: 19151754 [TBL] [Abstract][Full Text] [Related]
13. RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo. Zhang X; Deng HX; Zhao X; Su D; Chen XC; Chen LJ; Wei YQ; Zhong Q; Li ZY; He X; Yi T Oncology; 2009; 77(1):22-32. PubMed ID: 19440000 [TBL] [Abstract][Full Text] [Related]
14. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Lin H; Huber R; Schlessinger D; Morin PJ Cancer Res; 1999 Feb; 59(4):807-10. PubMed ID: 10029067 [TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival. Chandrasekher G; Sailaja D Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3577-88. PubMed ID: 15452065 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Peters MG; Farías E; Colombo L; Filmus J; Puricelli L; Bal de Kier Joffé E Breast Cancer Res Treat; 2003 Jul; 80(2):221-32. PubMed ID: 12908826 [TBL] [Abstract][Full Text] [Related]
17. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Cheng W; Tseng CJ; Lin TT; Cheng I; Pan HW; Hsu HC; Lee YM Carcinogenesis; 2008 Jul; 29(7):1319-26. PubMed ID: 18413366 [TBL] [Abstract][Full Text] [Related]
18. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation. Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698 [TBL] [Abstract][Full Text] [Related]
19. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Hua K; Feng W; Cao Q; Zhou X; Lu X; Feng Y Int J Oncol; 2008 Nov; 33(5):959-67. PubMed ID: 18949358 [TBL] [Abstract][Full Text] [Related]
20. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Capurro MI; Xiang YY; Lobe C; Filmus J Cancer Res; 2005 Jul; 65(14):6245-54. PubMed ID: 16024626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]